UroToday.com - Dr. Sandler reported on a secondary analysis of RTOG 85-31, in which the patients who got longer duration of ADT had better survival. In RTOG 9202, 1,554 men with T3 disease had either ADT for a mean of 28 months vs. short term ADT and there was a PCSM benefit to long term therapy. The benefit is seen most in high-risk patients. In the Harvard trial updated by D’Amico, there is a persistent PCSM advantage to those who received 6 months ADT vs. no ADT.